United Therapeutics Corp

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. Wh...

The iShares U.S. Pharmaceuticals ETF (IHE) outperformed the Simplify Health Care ETF (PINK) over the past year, delivering 42.40% returns versus 29.30%. IHE offers lower costs (0.38% expense ratio), higher dividend yield (1.62%), and focuses on established pharmaceutical giants like Eli Lilly and Johnson & Johnson. While PINK provides active mana...

Pinterest, Southwest Airlines, and United Therapeutics executed aggressive share buyback programs in Q1 2026, reducing their outstanding share counts by 16%, 5%, and 3.2% respectively. Pinterest spent $2 billion on repurchases despite being down 15% YTD, while Southwest spent $1.25 billion amid fuel cost headwinds. United Therapeutics utilized a ...

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics en...

Transplants.org, a new 501(c)(3) nonprofit, launched a technology-first platform to centralize organ and stem cell transplant education and navigation. Backed by over 25 leading U.S. transplant centers and governed by transplant directors from major medical institutions, the platform uses AI to transform thousands of pages of research materials i...